Abstract 433P
Background
Malignancies in AYAs are increasing with increasing their death occurrences but a few data from developing countries. There are 72006601(44.2%) people under 15-39 years age group in Bangladesh. They are in vital age group not only for their own development but also for their country and for the world. This study was aimed to find out the outcome of treatment and causes of death.
Methods
The study was an observational study. All cancer patients aged 15-39 years completed treatment at medical oncology department in National Institute of Cancer Research and Hospital (NICRH) from Jan.2016 to Dec.2017(24 months). Of them 593 patients were included for the study. Their follow up were taken over phone or departmental follow up registries up to May 2019. Information was prospectively studied.
Results
Total 593 patients were enrolled for this study, male(M) 295(49.75%), female(F)298(50.25%) and M:F=1:1.01. After follow up, found 170(28.67%) patients were untraceable whose 63(10.62%) patients had no contact number. Among the remaining 473 patients 170(35.94%) were died due to anorexia 162(95.3%), both nausea and vomiting 90(53%), pain and fever 65(38.24%), diarrhea 57(33.53%), respiratory distress 38(22.35%), cachexia 37(21.76%), bleeding and generalized swelling 18(10.60%), opportunistic infection 10(5.88%), stroke 3(1.176%), surgical complication 2(1.18%). Of the died patients male were 96, female were 74 and M:F was 1.3:1. The leading causes of death, according to specific disease, were lung cancer 11(61%), head neck cancer 12(57%), sarcoma 56(46%), GIT(gastrointestinal tract) cancer 39(40.63%) and leukemia 12(35%). Least death occurred in GCT (germ cell tumor) 1(4.34%) and lymphoma 7(9%). Alive patients were 240. Of them male were 84, female were 156 and the ratio was M:F=1:1.86. According to specific disease, the highest survival were in testicular malignancy 18(85.71%), breast cancer 88(71%), FGT (female genital tract) 26(70%), lymphoma 44(59%) and GIT malignancy42(43.75%).
Conclusions
Death occurrences were 170(35.94%) and tract out of follow up were 170(28.67%) in AYA that were dangerously alarming for developing countries as youth are majority of total population in developing countries.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Abdullah Al Mamun Khan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract